Ionis Pharmaceuticals (IONS) has put fresh clinical data for its triglyceride drug candidate olezarsen in front of investors, with new 24 month results from the CORE OLE study presented at the National Lipid Association Scientific Sessions.

The recent olezarsen data come as Ionis shares trade at US$73.28, with the stock down over the year to date but supported by a very large 1 year total shareholder return. This points to strong longer term momentum even as short term price returns have been mixed around recent conference appearances and the board appointment of Ludwig Hantson.

If you are looking beyond a single drug story and want to see what else is moving in healthcare AI, this is a good moment to scan 40 healthcare AI stocks

With Ionis shares down 8% year to date, but carrying a very large 1-year total return and trading at a sizeable discount to analyst targets and intrinsic estimates, is this a fresh opportunity or is future growth already priced in?

Most Popular Narrative: 27.4% Undervalued

Ionis closed at $73.28 against a widely followed fair value of $100.92, highlighting a valuation gap that depends on aggressive growth assumptions.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are described as potential drivers of sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage. Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, is presented as a basis for Ionis potentially capturing additional market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

Want to see what is included in that $100.92 fair value? The narrative uses assumptions about rapid revenue expansion, a shift from losses to profits, and a premium future earnings multiple.

Result: Fair Value of $100.92 (UNDERVALUED)

However, this hinges on key assumptions, and any setbacks for Tryngolza in broader severe hypertriglyceridemia or weaker than expected partner execution could quickly challenge that undervalued story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Angle on Valuation

The analyst narrative and fair value of $100.92 lean heavily on future earnings assumptions. Yet on simple sales-based metrics, Ionis looks expensive, with a P/S of 11.4x versus 10.3x for US biotech peers and a fair ratio of 5.3x, which points to meaningful valuation risk if sentiment cools.

That gap between today’s 11.4x and the 5.3x fair ratio is wide enough that any disappointment on revenue or margins could hit the share price harder than the analyst story suggests. It is therefore worth asking whether you are being paid enough for that extra risk.See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals on valuation and growth are raising questions for you, it could be worth acting now and weighing the potential rewards against the risks using the 2 key rewards.

Looking for more investment ideas?

If Ionis has sharpened your focus, do not stop here. Use the tools available to compare other opportunities and pressure test your thinking before you commit.

• Scan for potential mispriced opportunities by running the 44 high quality undervalued stocks that match your criteria and see which stocks stand out.
• Target stability first and check the 71 resilient stocks with low risk scores to spot companies with more resilient profiles and fewer red flags.
• Hunt for quality beyond the obvious, using the screener containing 20 high quality undiscovered gems that combine fundamentals with less crowded investor attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.